182 related articles for article (PubMed ID: 27916436)
1. Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study.
Brauer DG; Strand MS; Sanford DE; Kushnir VM; Lim KH; Mullady DK; Tan BR; Wang-Gillam A; Morton AE; Ruzinova MB; Parikh PJ; Narra VR; Fowler KJ; Doyle MB; Chapman WC; Strasberg SS; Hawkins WG; Fields RC
HPB (Oxford); 2017 Feb; 19(2):133-139. PubMed ID: 27916436
[TBL] [Abstract][Full Text] [Related]
2. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial.
Mackay TM; Smits FJ; Latenstein AEJ; Bogte A; Bonsing BA; Bos H; Bosscha K; Brosens LAA; Hol L; Busch ORC; Creemers GJ; Curvers WL; den Dulk M; van Dieren S; van Driel LMJW; Festen S; van Geenen EJM; van der Geest LG; de Groot DJA; de Groot JWB; Haj Mohammad N; Haberkorn BCM; Haver JT; van der Harst E; Hemmink GJM; de Hingh IH; Hoge C; Homs MYV; van Huijgevoort NC; Jacobs MAJM; Kerver ED; Liem MSL; Los M; Lubbinge H; Luelmo SAC; de Meijer VE; Mekenkamp L; Molenaar IQ; van Oijen MGH; Patijn GA; Quispel R; van Rijssen LB; Römkens TEH; van Santvoort HC; Schreinemakers JMJ; Schut H; Seerden T; Stommel MWJ; Ten Tije AJ; Venneman NG; Verdonk RC; Verheij J; van Vilsteren FGI; de Vos-Geelen J; Vulink A; Wientjes C; Wit F; Wessels FJ; Zonderhuis B; van Werkhoven CH; van Hooft JE; van Eijck CHJ; Wilmink JW; van Laarhoven HWM; Besselink MG;
Trials; 2020 Apr; 21(1):334. PubMed ID: 32299515
[TBL] [Abstract][Full Text] [Related]
3. A Prospective Observational Study on the Structuring Process and Implementation of a Large Regional, Inter-hospital, Virtual Multidisciplinary Tumor Board on Prostate Cancer.
Valerio MR; Serretta V; Arico D; Fazio I; Altieri V; Baldari S; Pennisi M; Girlando A; Spada M; Gesolfo CS; Messina M; Messina C; Giorgia L; Sortino G; DI Grazia A; Guggino R; Borsellino N; Piazza D; Gebbia V
Anticancer Res; 2023 Jan; 43(1):501-508. PubMed ID: 36585190
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of economic evaluation in pancreatic ductal adenocarcinoma.
Gérard C; Fagnoni P; Vienot A; Borg C; Limat S; Daval F; Calais F; Vardanega J; Jary M; Nerich V
Eur J Cancer; 2017 Nov; 86():207-216. PubMed ID: 29024890
[TBL] [Abstract][Full Text] [Related]
5. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
[TBL] [Abstract][Full Text] [Related]
6. The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center.
Quero G; Salvatore L; Fiorillo C; Bagalà C; Menghi R; Maria B; Cina C; Laterza V; Di Stefano B; Maratta MG; Ribelli M; Galiandro F; Mattiucci GC; Brizi MG; Genco E; D'Aversa F; Zileri L; Attili F; Larghi A; Perri V; Inzani F; Gasbarrini A; Valentini V; Costamagna G; Manfredi R; Tortora G; Alfieri S
ESMO Open; 2021 Feb; 6(1):100010. PubMed ID: 33399076
[TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary Management of Hepatocellular Carcinoma Improves Access to Therapy and Patient Survival.
Agarwal PD; Phillips P; Hillman L; Lucey MR; Lee F; Mezrich JD; Said A
J Clin Gastroenterol; 2017 Oct; 51(9):845-849. PubMed ID: 28877082
[TBL] [Abstract][Full Text] [Related]
8. The utilization of multidisciplinary tumor boards (MDT) in clinical routine: results of a health care research study focusing on patients with metastasized colorectal cancer.
Lowes M; Kleiss M; Lueck R; Detken S; Koenig A; Nietert M; Beissbarth T; Stanek K; Langer C; Ghadimi M; Conradi LC; Homayounfar K
Int J Colorectal Dis; 2017 Oct; 32(10):1463-1469. PubMed ID: 28779354
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma.
Alemi F; Alseidi A; Scott Helton W; Rocha FG
Curr Probl Surg; 2015 Sep; 52(9):362-98. PubMed ID: 26363649
[No Abstract] [Full Text] [Related]
10. Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.
Pai RK; Pai RK
Mod Pathol; 2018 Jan; 31(1):4-23. PubMed ID: 28776577
[TBL] [Abstract][Full Text] [Related]
11. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
12. Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide.
El Saghir NS; Keating NL; Carlson RW; Khoury KE; Fallowfield L
Am Soc Clin Oncol Educ Book; 2014; ():e461-6. PubMed ID: 24857140
[TBL] [Abstract][Full Text] [Related]
13. Association of facility type with overall survival in patients with nonsurgically managed pancreatic cancer.
McAllister J; Amin S; Lin C
Future Oncol; 2022 Mar; 18(10):1273-1284. PubMed ID: 35114803
[TBL] [Abstract][Full Text] [Related]
14. Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma.
Swords DS; Mulvihill SJ; Firpo MA; Scaife CL
JAMA Oncol; 2018 Aug; 4(8):1129-1130. PubMed ID: 30003235
[TBL] [Abstract][Full Text] [Related]
15. A pancreatic cancer multidisciplinary clinic: insights and outcomes.
Schiffman SC; Abberbock S; Winters S; Valko C; Steve J; Zureikat AH; Zeh HJ; Hogg ME
J Surg Res; 2016 May; 202(2):246-52. PubMed ID: 27229097
[TBL] [Abstract][Full Text] [Related]
16. Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally.
Lutfi W; Zenati MS; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Jul; 25(7):1860-1867. PubMed ID: 29691733
[TBL] [Abstract][Full Text] [Related]
17. An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma.
Castel-Kremer E; De Talhouet S; Charlois AL; Graillot E; Chopin-Laly X; Adham M; Comte B; Lombard-Bohas C; Walter T; Boschetti G
J Geriatr Oncol; 2018 Jul; 9(4):373-381. PubMed ID: 29685381
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment.
Winer LK; Cortez AR; Ahmad SA; Wima K; Olowokure O; Latif T; Kharofa J; Patel SH
J Surg Res; 2021 Mar; 259():442-450. PubMed ID: 33059910
[TBL] [Abstract][Full Text] [Related]
19. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.
Katsuda M; Miyazawa M; Ojima T; Katanuma A; Hakamada K; Sudo K; Asahara S; Endo I; Ueno M; Hara K; Yamada S; Fujii T; Satoi S; Ioka T; Ohira M; Akahori T; Kitano M; Nagano H; Furukawa M; Adachi T; Yamaue H
Trials; 2019 Apr; 20(1):242. PubMed ID: 31029154
[TBL] [Abstract][Full Text] [Related]
20. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
